Search company, investor...

Founded Year

2014

Stage

Series B - II | Alive

Total Raised

$8.85M

Last Raised

$2.77M | 6 yrs ago

About ClearLight Diagnostics

ClearLight Diagnostics is a company focused on biotechnology, specifically in the domain of tissue processing and 3D imaging. The company offers products such as tissue clearing kits and consulting services for researchers in the field of CLARITY tissue clearing and 3D immunohistochemistry. ClearLight primarily serves the research and scientific community. It was founded in 2014 and is based in Sunnyvale, California.

Headquarters Location

428 Oakmead Parkway

Sunnyvale, California, 94085,

United States

800-251-8905

Loading...

Loading...

ClearLight Diagnostics Patents

ClearLight Diagnostics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/2/2016

Oncology, Molecular biology, Clusters of differentiation, Transcription factors, Cell biology

Application

Application Date

12/2/2016

Grant Date

Title

Related Topics

Oncology, Molecular biology, Clusters of differentiation, Transcription factors, Cell biology

Status

Application

Latest ClearLight Diagnostics News

ClearLight Diagnostics to Present Data on the 3D Imaging of Biomarkers in Core Needle Biopsies of Breast Cancer Patients

Dec 4, 2017

Share this article SUNNYVALE, Calif., Dec. 4, 2017 /PRNewswire/ -- ClearLight Diagnostics, LLC, a developer of an automated next generation tissue processing and 3D imaging platform, announced today that it will present data at the 2017 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. Poster title: Three-dimensional (3D) Imaging of Biomarkers in Human Core Needle Biopsies of Normal and Cancerous Breast Tissue Authors: Yi Chen, Qi Shen, Laurie J. Goodman, Yesim Gokmen-Polar, Sunil Badve The tumor microenvironment is spatially and compositionally very heterogeneous, which introduces great challenges to characterize when limited to analyzing samples using standard 2D thin section FFPE methods. Capturing high resolution 3D quantitative biomarker data, while simultaneously preserving morphology of the tumor microenvironment, could lead to a better understanding of key spatial relationships and may lead to better prognostic and predictive clinical outcomes. In this study, we utilized a novel technique, CLARITY, to transform core needle biopsies from patients with breast cancer, into optically transparent tissues, followed by multiplexed immunostaining and 3D imaging of molecular markers. This data was compared to the conventional methods of immunohistochemistry and immunofluorescence staining on FFPE thin sections. This is the first study demonstrating that other than fresh or frozen tissues, pre-fixed clinical tissue from patients with breast cancer, can be successfully processed by the CLARITY method and 3D imaged, indicating the potential power of this technique for core needle biopsy tissue processing and the identification of biomarkers based on tumor cell heterogeneity. Abstract #351 Session Title: Tumor cell and molecular biology: Microenvironments-stromal epithelial interaction Program Number: P5-03-02 ClearLight Diagnostics is a technology development company focused on the discovery, development, and commercialization of innovative technologies to significantly improve the diagnosis and treatment of a wide range of diseases with an initial focus in oncology. Founded by Karl Deisseroth M.D., Ph.D., ClearLight is developing an integrated instrumentation platform with the associated optimized biomarker panels based on the CLARITY lipid-clearing technique developed by Dr. Deisseroth and colleagues at Stanford University. This technique enables the transformation of tissue into a nanoporous, hydrogel-hybridized form that is crosslinked to a three-dimensional network of hydrophilic polymers. The process produces a fully assembled, intact tissue, which is permeable to macromolecules and optically transparent, thus allowing for robust three-dimensional imaging of subcellular components (DNA, RNA and protein) and heterogeneous cellular interactions within the tumor microenvironment. This technology, paired with the development of a tissue imaging platform that includes the revolutionary microscopy method, COLM (CLARITY Optimized Light-sheet Microscopy) will enable unprecedented depth and acceleration of image collection from lipid-cleared samples interrogated with biomolecules. Visit us at www.clearlightdx.com .

ClearLight Diagnostics Frequently Asked Questions (FAQ)

  • When was ClearLight Diagnostics founded?

    ClearLight Diagnostics was founded in 2014.

  • Where is ClearLight Diagnostics's headquarters?

    ClearLight Diagnostics's headquarters is located at 428 Oakmead Parkway, Sunnyvale.

  • What is ClearLight Diagnostics's latest funding round?

    ClearLight Diagnostics's latest funding round is Series B - II.

  • How much did ClearLight Diagnostics raise?

    ClearLight Diagnostics raised a total of $8.85M.

  • Who are the investors of ClearLight Diagnostics?

    Investors of ClearLight Diagnostics include Wiegers Capital Partners.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.